Annexon Inc. (ANNX) Price to Earnings Multiple
Annexon, Inc. (ANNX) biotechnological developments are protected by an extensive portfolio of patents, while high R&D expenditures and stringent FDA oversight create a significant barrier to entry for new players. The company develops treatments for autoimmune pathologies and nerve tissue degeneration, diversifying risks across its ophthalmology and neurology pipelines. This price chart with the -3.90 indicator complements data regarding a closed laboratory ecosystem dependent on external financing.
Analytical breakdowns for Annexon, Inc.
- price and consensus price forecast:
- market capitalization details:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Ratio Annexon, Inc.|ANNX - Long-Term Debt to Equity|Current Liabilities to Capital Annexon Biosciences Inc.|ANNX - Company Debts|Debt to Book Value Ratio Annexon Biosciences|ANNX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Annexon|Interim Coverage Ratio annexonbio.com
- financial results and valuation multiples details:
ANNX - Company Net Income|Net Profit Forecast Annexon, Inc.|ANNX - P/E Multiple|Projected Price to Earnings Annexon Biosciences|ANNX - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Annexon Biosciences|ANNX - Operating profit EBITDA|Net earnings per share (EPS TTM) Annexon|ANNX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months annexonbio.com|ANNX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Annexon, Inc.
Comprehensive company analysis:annexonbio.com ANNX
The P/E ratio reflects the market value of a single unit of profit, allowing for a real-time assessment of the actual return on investment. For Annexon, Inc. (ANNX), this metric is critical due to the massive clinical trial expenses that are temporarily suppressing net income. The company's P/E dynamics visualize the transition from a high-cost stage to the expected monopoly margins following FDA approval. Analyzing this curve helps investors determine the fair value point of the asset.
Competing companies
P/E Multiple biogen.com|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|Regencell Bioscience Ltd - Price to Earnings Multiple|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACAD: Price to Earnings Multiple|Xenon Pharmaceuticals - P/E Multiple|Market Cap to Earnings vikingtherapeutics.com|SUPN (Supernus) - Price to Earnings Ratio|Price to Earnings Multiple CPRX|Price to Earnings Ratio Denali Therapeutics Inc|Market Cap to Earnings Harmony Corp HRMY|Price to Earnings Ratio Biohaven Ltd. (BHVN)|amylyx.com - Price to Earnings Multiple|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|Business Payback Period CeriBell EEG CBLL|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Multiple ALEC|OMER (Omeros Corp) - P/E Multiple|Price to Earnings Ratio Neurogene Inc (NGNE)|Price to Earnings Ratio ACIU (AC Immune Corp)|Business Payback Period Voyager Corp|P/E Multiple NMRA (Neumora Therapeutics)|P/E Multiple scilexholding.com SCLX|TVGN - Price to Earnings Ratio|ACOG (Alpha Cognition) - Price to Earnings Multiple|Cognition Therapeutics, Inc. (CGTX) - Price to Earnings Ratio|Price to Earnings Multiple IKT|Price to Earnings Ratio SAVA|Price to Earnings Multiple ASRT (Assertio Therapeutics)|Price to Earnings Ratio Coya Therapeutics, Inc. (COYA)|vistagen.com - Price to Earnings Multiple|P/E Multiple OVID (Ovid Therapeutics)|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Earnings|CRVO: Price to Earnings Ratio|ATHE - P/E Multiple|clene.com (CLNN) - Price to Earnings Ratio|PepGen - Company Value to Net Income|Price to Earnings Ratio Jupiter Neurosciences|Market Cap to Earnings Relmada Corp RLMD|P/E Multiple ANVS|P/E Multiple gracetx.com (GRCE)|Price to Earnings Ratio Firefly Neuroscience AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH (Reviva Pharmaceuticals, Inc.) - Price to Earnings Multiple|MTVA: P/E Multiple|Market Cap to Earnings neuraxis.com (NRXS)|Price to Earnings Ratio HSDT|Price to Earnings Multiple PASG (Passage Bio Corp)|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|NERV - Market Cap to Earnings|Price to Earnings Ratio Athira Pharma, Inc. ATHA|ADXN: Price to Earnings Multiple|ALZN: Price to Earnings Ratio|Company Value to Net Income CYCN (Cyclerion Therapeutics)|PTIX: P/E Multiple|KTTA - Business Payback Period|Price to Earnings Ratio Cortigent Inc|Price to Earnings Multiple ATXI (avenuetx.com)|P/E Multiple BCLI|Price to Earnings Ratio Cara Therapeutics Inc. CARA|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Business Payback Period Eliem Therapeutics, Inc. (ELYM)|Intra-Cellular - P/E Multiple|LBPH - P/E Multiple|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|Price to Earnings Multiple NKGN|Price to Earnings Ratio NeuroBo|Price to Earnings Multiple SAGE (Sage Therapeutics Inc)|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|trevena.com - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|WENA: Price to Earnings Multiple|Cerevel - P/E Multiple
